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First there is a mountain, then there is no mountain, then there is.
eZen proverb and song by Donavan, British singer (1968)
By the beginning of the 19th century, tuberculosis had
killed 1 in 7 of all individuals who had ever lived. In Europe,
rates of tuberculosis began to rise in the early 17th century to
a peak level in the 19th century, when it caused nearly 25% of
all deaths. Among writers, Jane Austen, the Brontë sisters,
John Keats, Elizabeth Browning, Anton Chekhov, Albert
Camus, Franz Kafka, Henry David Thoreau, and George
Orwell all succumbed. Urban poverty and overcrowding were
strong risk factors for tuberculosis, but its reach extended to all
levels of society.
In what is generally considered to be the ﬁrst randomized
controlled clinical trial in medicine, streptomycin was shown
to reduce mortality in a series of young patients with active
pulmonary tuberculosis.1 However, by the time this study was
published in 1948, the threat from tuberculosis had largely
receded in Europe and North America. A better under-
standing of the pathophysiology of the disease, improved
living conditions, better diagnosis, isolation of active cases,
and better treatment all are assumed to have contributed to
the decline in tuberculosis incidence and mortality.
Myocardial infarction was ﬁrst clearly described in 1912.2
The incidence of coronary heart disease (CHD) increased
rapidly over the ensuing decades, peaking in the mid-1960s in
North America and about a decade later in Western Europe.
In 1977, it was belatedly recognized that CHD mortality had
been falling in the United States for more than a decade, with
an age-adjusted decline of approximately 25% across all age
groups.3 Since then, both the incidence and the case fatality
rate of CHD have steadily decreased in the United States,
with reductions in age-adjusted CHD mortality between 1980
and 2009 of 66% in men and 67% in women.4 The incidence
of stroke peaked earlier and has shown similar declines.
In this issue of the Canadian Journal of Cardiology, Tu
et al.5 describe the changes between 1994 and 2014 in hos-
pitalization rates in Ontario for 6 major atherosclerotic car-
diovascular disease (ASCVD) conditions and trends in
mortality rates for ischemic heart disease, cerebrovascular
disease, and noncirculatory disease. This information is
derived mainly from the Canadian Institute for Health In-
formation Hospital Discharge Abstract Database and serial
Canadian Community Health Surveys.
The changes over these 2 decades are breathtaking. Age-
standardized hospitalizations for the 6 ASCVD conditions
decreased by 54% in both men and women. Ischemic heart
disease and cerebrovascular disease mortality decreased by
53% in both sexes, whereas noncardiovascular mortality
declined by “only” 22%. During this period, age-standardized
rates of percutaneous coronary intervention (PCI) increased
from approximately 100 to > 300 per 100,000 population in
men and from approximately 40 to 110 per 100,000 popu-
lation in women, whereas the rates or coronary bypass surgery
fell to a lesser extent.
How Do We Explain These Improvements?
Tu et al.5 attribute the fall in ASCVD hospitalizations and
mortality to better control of risk factorsdspeciﬁcally,
smoking, hypertension, and greater use of cholesterol-
lowering therapydalong with increasing rates of PCI. As
they point out, similar improvements have been described
over this period in the United States and Western Europe,
although not simultaneously for all 6 of the ASCVD condi-
tions tracked in this study.
Several investigators have provided precise estimates of the
contributions of different factors to the fall in CHD mortality.
For example, 1 group stated that 25% of the decline in CHD
mortality from 1980-1990 could be attributed to primary
prevention, whereas 29% was explained by a secondary
reduction in risk factors in patients with CHD and 43% by
other improvements in the treatment of patients with CHD.6
In serial population surveys from Norway, the incidence of
CHD decreased by 3% per year between 1994 and 2008.7
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Changes in coronary risk factors accounted for 66% of the
decline, with improvements in cholesterol levels contributing
32%, whereas reduced blood pressure, giving up smoking, and
physical activity contributed 14%, 13%, and 9%, respectively.
Although studies such as these appear highly credible, in
part because they provide a high degree of precision, they in
fact describe associations and do not prove causality. Never-
theless, plans to reduce ACSVD usually revolve around risk
factor reduction strategies. In the United States, eg, Healthy
People 2020 aims to reduce fatal ASCVD by 20% by 2020,
with a strategy based mainly on risk factor reduction.8
The New Mountain
Although tuberculosis was conquered in the ﬁrst half of the
20th century, it did not vanish but only retreated to niches
where it could thrive, such as disadvantaged inner cities,
Canadian aboriginal communities, and developing countries.
The spread of HIV has led to a resurgence of tuberculosis. In
1997 worldwide, new cases of tuberculosis totaled almost
8 million, with 1.87 million deaths and a global case fatality
rate of 23%.9 Latent tuberculosis is present in approximately
2 billion individuals across the globe.
There are ominous signs to suggest that ASCVD is not
about to fade from view either. Tu et al.5 note that the rates of
decline in ASCVD “were least evident among those aged
20-49 for both sexes.” Reports from the United States, the
United Kingdom, and Australia also indicate that ASCVD
rates are not decreasing and indeed in some instances appear
to be increasing slightly in younger age strata, particularly in
women.10-13 A change in the case fatality rate does not appear
to account for the ﬂattening or increased CHD mortality
curve in younger groups; rather, this more likely results from
an increase in risk factors,13 speciﬁcally surging rates of obesity
and diabetes.
More than 80% of deaths from ASCVD now occur in low-
and middle-income countries, where the incidence continues
to rise.14,15 Rates of ASCVD and ASCVD mortality are
higher in low- and middle-income countries compared with
high-income countries, despite a lower risk factor burden.15
The obvious reason for this disparity is the very low rates of
treatment of risk factors in low- and middle-income countries
and lower rates of coronary revascularization compared with
high-income countries.15 Furthermore, risk factors are
becoming more prevalent in low- and middle-income coun-
tries, presaging a worsening of their ASCVD epidemics.16
Social Deprivation
The relationship between childhood deprivation and life
expectancy is most colorfully depicted in a map of the London
Underground created by the geographer James Cheshire in
2012, with life expectancy shown at each Underground
stop.17 Going east on the Central Line for 8 stops, between
Oxford Circus and Mile End, life expectancy decreases by 18
years, and crossing the Thames between the Pimlico and
Vauxhall stations sees life expectancy drop by 6 years.
Social deprivation, both on a country level and for disad-
vantaged groups within a country, has long been linked to an
increased risk of ACSVD. However, higher risk is not limited
to just the lowest stratum of deprivation. In the inﬂuential
Whitehall study of 17,530 British civil servants, all of whom
were employed and none of whom were considered to be
socially deprived, 10-year CHD mortality was 2.2%, 3.6%,
4.9%, and 6.7% across job grade from the highest to the
lowest, a difference that remained statistically signiﬁcant even
after controlling for risk factors.18
Lack of access to affordable effective health care contributes
to social deprivation. Living in a disadvantaged neighborhood
compared with an advantaged one increases the risk of a
coronary event, even after adjustment for personal socioeco-
nomic status.19 Social support and social networks are often
deﬁcient for individuals experiencing social deprivation. In a
study of 32,624 male health care professionals, those in the
lowest stratum of social support had a relative risk of 1.9 for
cardiovascular mortality and 2.2 for incident stroke compared
with those in the highest stratum.20
Social deprivation may increase cardiovascular risk by
increasing depression and anxiety.21 Depression and depres-
sive symptoms have been linked to increased cardiovascular
morbidity and mortality in many studies, and the effect per-
sists after adjustment for other risk factors.21 In patients with
cardiovascular disease (CVD), depression is associated with
higher levels of inﬂammatory markers and other biomarkers of
risk, greater platelet reactivity, reduced heart rate variability,
and impaired vascular function.21
Future Directions
Further reductions in ASCVD incidence and mortality
should not be taken for granted. We must apply secondary
prevention more comprehensively. Among patients with
established ASCVD in the United States, statin drug use was
at 49.8% in 2002-2003 and despite a decrease in cost,
increased to only 58.1% in 2012-2013, with less than one-
third of patients prescribed a high-intensity statin drug.22
We must pay attention not just to primary prevention but
to primordial preventiondthe prevention of the appearance
of risk factors. This leads us to focus on young adults and
children. Although we treat individuals, we must also engage
in population-based initiatives to improve community health
and reduce socioeconomic disparities.
The prevalence of both tuberculosis and atherosclerosis are
strongly inﬂuenced by social determinants of health. The
World Health Organization broadly deﬁnes the social de-
terminants of health as the circumstances in which people are
born, grow, live, work, and age and the systems put in place to
deal with illness.23 We need to see ASCVD in this larger
context, just as we have with tuberculosis. We must shrink the
mountain and not just have it move somewhere else.
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